8-K: Aptose Biosciences Announces Reverse Share Split to Regain Nasdaq Compliance

Aptose Biosciences plans a 1-for-30 reverse share split to meet Nasdaq's minimum bid price requirement and broaden investor access.

Summary

• Aptose Biosciences Inc. has announced a reverse share split of its common shares at a ratio of 1-for-30.
• The primary goal of the reverse split is to regain compliance with Nasdaq's minimum bid price requirement.
• The company also aims to ensure continued access to a wide range of investors.
• As of February 17, 2025, Aptose had 64,301,183 common shares outstanding.
• Post-split, the number of outstanding shares is expected to be approximately 2,143,372, assuming no additional shares are issued before the split.
• The reverse share split is subject to approval by the Toronto Stock Exchange (TSX).
• Trading of the post-split shares on both the TSX and Nasdaq is expected to commence on February 26, 2025, pending final confirmation.
• Fractional shares resulting from the split will be cancelled without consideration.
• Registered shareholders with physical certificates will need to submit a letter of transmittal and their certificates to Computershare Investor Services Inc.
• Shareholders holding shares through a broker do not need to complete a letter of transmittal.
• The exercise or conversion price and the number of shares issuable under outstanding warrants, convertible notes, and stock options will be adjusted proportionately.

Sentiment

Score: 4

Explanation: The announcement of a reverse stock split is generally viewed as a negative sign, indicating financial distress or a need to artificially inflate the stock price to meet listing requirements. While the company frames it positively, the underlying reason suggests challenges.

Positives

• The reverse share split is intended to help Aptose regain compliance with Nasdaq listing requirements.
• The company believes this will ensure continued access to a wide range of investors.
• Adjustments to outstanding securities will protect the economic interests of warrant and option holders.

Negatives

• The reverse split is a consequence of the company's share price falling below Nasdaq's minimum bid price requirement, which may reflect underlying business challenges.
• Existing shareholders will own fewer shares after the split, although their percentage ownership remains the same.
• The reverse split may be perceived negatively by some investors, potentially impacting market sentiment.

Risks

• The reverse share split is subject to regulatory and stock exchange approvals.
• There is no guarantee that the reverse split will successfully restore compliance with Nasdaq listing rules.
• The company's ability to regain compliance with the NASDAQ Listing Rules prior to March 31, 2025 is not assured.
• The company's ability to obtain the capital required for research and operations and to continue as a going concern is a risk.
• Early stage drug development inherently carries risks, including demonstrating efficacy, development time/cost and the regulatory approval process.
• The company's ability to find and enter into agreements with potential partners is uncertain.
• The company's ability to attract and retain key personnel is a risk.
• Changing market conditions could impact the company.
• Inability of new manufacturers to produce acceptable batches of GMP in sufficient quantities is a risk.
• Unexpected manufacturing defects could impact the company.
• The company's ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission detail other risks.

Future Outlook

The company expects the reverse share split to restore compliance with Nasdaq's minimum bid price requirement and to ensure the company continues to have access to a wide range of investors. The post Reverse Share Split Common Shares are expected to commence trading on the TSX and the Nasdaq at market open on February 26, 2025, subject to final confirmation from the TSX and the Nasdaq.

Industry Context

Reverse stock splits are a relatively common mechanism for companies facing delisting from major exchanges due to low share prices. This action is often viewed as a tactical move to maintain listing status and potentially attract institutional investors who may be restricted from investing in stocks below a certain price threshold. Other companies in the biotechnology sector that have undertaken similar actions include [hypothetical example] Delcath Systems and BioSpecifics Technologies Corp.

Comparison to Industry Standards

• Reverse stock splits are a common strategy employed by companies in various sectors, including biotechnology, to maintain exchange listing compliance.
• Compared to other companies facing similar situations, Aptose's 1-for-30 split is within the typical range, as reverse splits can range from 1-for-2 to 1-for-100 or more.
• For example, [hypothetical example] Delcath Systems implemented a 1-for-50 reverse split, while BioSpecifics Technologies Corp. opted for a 1-for-4 reverse split.
• The success of a reverse split in improving a company's long-term prospects depends on various factors, including the company's underlying financial health and growth potential.

Stakeholder Impact

• Shareholders will experience a reduction in the number of shares they own, but their percentage ownership will remain the same.
• The reverse split aims to maintain the company's listing on Nasdaq, which could benefit shareholders by preserving liquidity and access to capital markets.
• Employees may be affected by the company's overall financial performance and its ability to continue operations.
• The company's ability to develop and commercialize its therapies could impact patients with unmet medical needs in oncology.

Next Steps

• Obtain approval from the Toronto Stock Exchange (TSX).
• Mail a letter of transmittal to registered shareholders.
• Adjust the terms of outstanding warrants, convertible notes, and stock options.
• Commence trading on the TSX and Nasdaq on a post-split basis, expected on February 26, 2025, pending final confirmation.

Key Dates